

# Brett Lauring

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7027882/publications.pdf>

Version: 2024-02-01

15  
papers

1,118  
citations

759233

12  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

762  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes, Obesity and Metabolism, 2019, 21, 1474-1482.	4.4	38
2	Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Current Medical Research and Opinion, 2019, 35, 1335-1343.	1.9	32
3	Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes, Obesity and Metabolism, 2019, 21, 1027-1036.	4.4	48
4	Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Therapy, 2018, 9, 253-268.	2.5	68
5	Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, Obesity and Metabolism, 2018, 20, 1453-1460.	4.4	70
6	Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1111-1120.	4.4	121
7	Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Therapy, 2018, 9, 193-207.	2.5	86
8	Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (<scp>VERTIS MET</scp>). Diabetes, Obesity and Metabolism, 2018, 20, 520-529.	4.4	136
9	Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The <scp>VERTIS SITA2</scp> placebo-controlled randomized study. Diabetes, Obesity and Metabolism, 2018, 20, 530-540.	4.4	121
10	Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Therapy, 2018, 9, 49-66.	2.5	99
11	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal, 2018, 206, 11-23.	2.7	171
12	Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. Diabetes, 2018, 67, 1145-P.	0.6	3
13	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes, Obesity and Metabolism, 2017, 19, 721-728.	4.4	113
14	Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers. Journal of Clinical Pharmacology, 2014, 54, 765-775.	2.0	4
15	Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. Journal of Clinical Pharmacology, 2014, 54, 1247-1255.	2.0	8